Salbutamol-Pharmstandart, aerosol 100 mcg/dose 200 doses

Salbutamol is a selective β₂-adrenoreceptor agonist (β₂-adrenomimetic). In therapeutic doses it acts on β₂-adrenoreceptors of bronchial smooth muscle, having little or no effect on β₁-adrenoreceptors of the myocardium.

It has a pronounced bronchodilator effect, preventing or arresting bronchial spasm, reduces resistance in the airways. Increases the vital capacity of the lungs. Increases mucociliary clearance (in chronic bronchitis up to 36%), stimulates mucus secretion, activates the functions of the intermittent epithelium.

In recommended therapeutic doses does not have adverse effects on the cardiovascular system, does not cause an increase in blood pressure. To a lesser extent compared to the drugs of this group, it has positive chrono- and inotropic effects. It causes dilation of the coronary arteries.

It has a number of metabolic effects: it reduces the concentration of potassium in the blood plasma, affects glycogenolysis and insulin release, has hyperglycemic (especially in patients with bronchial asthma) and lipolytic effects, increases the risk of acidosis.

After using an inhaled dose of salbutamol, the action develops quickly, the beginning of the effect – in 5 minutes, the maximum effect – in 30-90 minutes (75% of the maximum effect is reached within 5 minutes), duration – 4-6 hours.

Indications

1. Bronchial asthma:

• relief of attacks of bronchial asthma, including exacerbation of severe bronchial asthma;

• prevention of bronchospasm attacks associated with exposure to an allergen or caused by physical activity;

• use as one of the components in long-term maintenance therapy of bronchial asthma.

2. Chronic obstructive pulmonary disease (COPD), accompanied by reversible airway obstruction, chronic bronchitis.

Pharmacological effect

Salbutamol is a selective β2-adrenergic receptor agonist (β2-adrenergic agonist). In therapeutic doses, it acts on β2-adrenergic receptors of bronchial smooth muscle, having little or no effect on β1-adrenergic receptors of the myocardium.

It has a pronounced bronchodilator effect, preventing or relieving bronchospasm, and reduces resistance in the respiratory tract. Increases vital capacity of the lungs. Increases mucociliary clearance (in chronic bronchitis up to 36%), stimulates mucus secretion, activates the functions of the ciliated epithelium.

In recommended therapeutic doses, it does not have a negative effect on the cardiovascular system and does not cause an increase in blood pressure. To a lesser extent compared to drugs of this group, it has a positive chrono- and inotropic effect. Causes dilation of the coronary arteries.

It has a number of metabolic effects: it reduces the concentration of potassium in the blood plasma, affects glycogenolysis and insulin secretion, has hyperglycemic (especially in patients with bronchial asthma) and lipolytic effects, and increases the risk of developing acidosis.

After using an inhalation dose of salbutamol, the effect develops quickly, the onset of the effect is after 5 minutes, the maximum is after 30-90 minutes (75% of the maximum effect is achieved within 5 minutes), the duration is 4-6 hours.

Special instructions

Patients should be instructed on the correct use of Salbutamol. Correct use of the drug and strict adherence to the instructions are necessary to ensure that salbutamol enters the bronchi. At the beginning of treatment, the drug should be used under the supervision of medical personnel and after training in front of a mirror.

Active ingredient

Salbutamol

Composition

Composition for 1 dose:

Active substance:

Salbutamol sulfate

(in terms of salbutamol)

0.120 mg

(0.100 mg)

Excipients:

Ethanol (absolute ethyl alcohol)

5.905 mg

Oleic acid

0.009 mg

Propellant R 134a (1,1,1,2-tetrafluoroethane)

67.966 mg

Pregnancy

Salbutamol can be prescribed to pregnant women only if the expected benefit to the patient outweighs the potential risk to the fetus.

Contraindications

Hypersensitivity to the active substance or any other component of the drug.
Management of premature birth.
Threatened abortion.
Children under 2 years of age.

With caution

Salbutamol-Pharmstandard should be used with caution in patients with thyrotoxicosis, tachyarrhythmia, myocarditis, heart defects, aortic stenosis, coronary heart disease, severe chronic heart failure, arterial hypertension, pheochromocytoma, decompensated diabetes mellitus, glaucoma, as well as during pregnancy and breastfeeding.

Side Effects

By frequency, side effects can be divided into the following categories: very common (>1/10), common (>1/100 and 1/1000 and 1/10,000 and <1/100), very rare (<1/10,000).

Interaction

It is not recommended to use salbutamol and non-selective ß-adrenergic receptor blockers simultaneously, such as propranolol.
Salbutamol is not contraindicated in patients receiving monoamine oxidase inhibitors (MAOIs).

Overdose

Symptoms of overdose: more frequent – hypokalemia, decreased blood pressure, tachycardia, muscle tremors, nausea, vomiting; less frequent – ​​agitation, hyperglycemia, respiratory alkalosis, hypoxemia, headache; rare – hallucinations, convulsions, tachyarrhythmia, ventricular flutter, dilatation of peripheral vessels.

Storage conditions

Store at a temperature not exceeding 25°C.

Shelf life

2 years. Do not use after expiration date.

Manufacturer

Pharmstandard-Leksredstva, Russia